InspireMD Valuation Multiples

InspireMD Overview

About InspireMD

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

Founded

2008

HQ

Employees

86

Website

inspiremd.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $10M

EBITDA: ($42M)

EV

$10M

Valuation Multiples

Multiples.vc

Start free trial

InspireMD Financials

InspireMD reported last 12-month revenue of $10M and negative EBITDA of ($42M).

In the same LTM period, InspireMD generated $4M in gross profit, ($42M) in EBITDA losses, and had net loss of ($53M).

InspireMD P&L

In the most recent fiscal year, InspireMD reported revenue of $9M and EBITDA of ($38M).

InspireMD expects next 12-month revenue of XXX and NTM EBITDA of XXX

InspireMD Stock Performance

InspireMD has current market cap of $61M, and enterprise value of $10M.

InspireMD's stock price is $1.31.

InspireMD Valuation Multiples

InspireMD trades at 1.0x EV/Revenue multiple, and (0.2x) EV/EBITDA.

InspireMD Financial Valuation Multiples

As of April 11, 2026, InspireMD has market cap of $61M and EV of $10M.

Equity research analysts estimate InspireMD's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

InspireMD has a P/E ratio of (1.2x).

InspireMD Margins & Growth Rates

InspireMD's revenue in the last 12 month grew by 70%.

InspireMD's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.6M for the same period.

InspireMD's rule of 40 is (331%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

InspireMD's rule of X is (248%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

InspireMD Public Comps

See public comps and valuation multiples for other Medical Devices comps.

InspireMD M&A Activity

InspireMD acquired XXX companies to date.

Last acquisition by InspireMD was on XXXXXXXX, XXXXX. InspireMD acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

InspireMD Investment Activity

InspireMD invested in XXX companies to date.

InspireMD made its latest investment on XXXXXXXX, XXXXX. InspireMD invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).